Clinical antifungal efficacy trials in invasive aspergillosis: Consensus standards for trial design and room for...

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Trials

Background:

• Invasive aspergillosis presents significant treatment challenges with high mortality rates.
• Voriconazole trials set a benchmark for clinical trial methodology in invasive aspergillosis.
• Liposomal amphotericin B is a critical antifungal agent for invasive aspergillosis.

Purpose of the Study:

• To compare the efficacy and safety of a standard daily dose versus a high loading dose of liposomal amphotericin B.
• To refine clinical trial methodologies for invasive aspergillosis studies.
• To identify strategies for improving patient recruitment and trial efficiency.

Main Methods:

• A randomized trial comparing two liposomal amphotericin B dosing regimens (3 mg/kg/day vs. 10 mg/kg/day).
• Utilized strict eligibility and outcome assessment criteria, similar to previous reference trials.
• Incorporated a flexible case definition strategy to expedite patient recruitment.

Main Results:

• The trial demonstrated the feasibility of applying rigorous methodology to liposomal amphotericin B studies.
• The flexible case definition strategy significantly reduced patient recruitment time.
• The study provides data for optimizing liposomal amphotericin B dosing in invasive aspergillosis.

Conclusions:

• Rigorous trial design is crucial for advancing invasive aspergillosis treatment.
• Innovative recruitment strategies can enhance trial efficiency.
• Future trials should consider standardized biomarkers and prognostic factor stratification for improved results.